Teva/Ivax closing date extended
Executive Summary
The closing date for Teva's acquisition of Ivax has been extended, Teva announces Jan. 10; the consent order for the acquisition is still under review by the Federal Trade Commission, company reports. The two generics firms "have no reason to believe that the acceptance will not be forthcoming shortly, and expect to close the merger later this month." Teva announced the $7.4 bil. acquisition in July 2005 (1"The Pink Sheet" Aug. 1, 2005, p. 19)...
You may also be interested in...
Teva/Ivax Merger Will Create Significant Pricing Flexibility In Generics
Teva is prepared to leverage its $7.4 bil. acquisition of Ivax to offer the lowest prices on generic drugs "if need be," Ivax Chairman Phillip Frost said July 26 during a call regarding the deal
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.